---
title: "Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279082570.md"
description: "Capricor Therapeutics shares fell 8.6% to $30.54 after reporting a fourth-quarter loss of $30.2 million, significantly wider than analysts' expectations of a $500,000 revenue and a loss of 51 cents per share. The company did not generate any revenue during the quarter, down from $11.1 million a year earlier. Capricor is awaiting FDA approval for Deramiocel to treat Duchenne muscular dystrophy, with a response expected by August 22, 2026."
datetime: "2026-03-13T19:05:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279082570.md)
  - [en](https://longbridge.com/en/news/279082570.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279082570.md)
---

# Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

By Elias Schisgall

Shares of Capricor Therapeutics fell after the company posted a wider-than-expected loss in the fourth quarter after not bringing in any revenue.

Shares were down 8.6% to $30.54 in Friday afternoon trading. The stock has more than doubled in value in the past year.

The biotechnology company on Thursday posted a quarterly loss of $30.2 million, or 62 cents a share, compared with a loss of $7.12 million, or 16 cents a share, a year earlier.

Capricor did not post any revenue during the quarter, compared with $11.1 million a year prior.

The company said its primary sources of revenue were $40 million in upfront and first-development milestone payments and $10 million in second-development milestone payments per the company's distribution agreement with Nippon Shinyaku. Those payments were recognized as of year-end 2024, it said.

Analysts surveyed by FactSet were expecting $500,000 in revenue and a loss of 51 cents a share.

The company said it is continuing to work toward approval for Deramiocel to treat Duchenne muscular dystrophy. A biologics license application for the treatment is under review by the Food and Drug Administration, and the company expects a response from the agency by Aug. 22.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 13, 2026 14:48 ET (18:48 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [Key facts: FDA Approves EYLEA HD up to 20‑Week Dosing; REGN Revenue Slows](https://longbridge.com/en/news/282383303.md)